Associate Professor
Member, UCSF Helen Diller Family Comprehensive Cancer Center
Member, QB3
Departments of Medicine
Department of Cellular and Molecular Pharmacology
Primary Thematic Area
Secondary Thematic Area
Research Summary
Molecular characterization and precision treatment of solid cancers.
The Bivona lab conducts genetic and cell biological studies to uncover the fundamental principles that underlie the aberrant cell signaling events driving tumor initiation, progression, and drug resistance. The overall goal of this integrative research program is to understand the regulatory events underlying cancer cell growth through hypothesis-driven, laboratory-based investigations in order to improve cancer therapy and cancer patient survival.
Websites
Publications
Myeloid-mesenchymal crosstalk drives ARG1-dependent profibrotic metabolism via ornithine in lung fibrosis.
The Journal of clinical investigation
Reversible therapeutic resistance in EGFR mutant lung cancer caused by RB1 loss induced lineage plasticity.
bioRxiv : the preprint server for biology
Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Acquired resistance in cancer: towards targeted therapeutic strategies.
Nature reviews. Cancer
BRAFV600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling.
bioRxiv : the preprint server for biology
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Nature
FET fusion oncoproteins disrupt physiologic DNA repair networks and induce ATR synthetic lethality in cancer.
bioRxiv : the preprint server for biology
Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance.
Nature communications
Macrophage-fibroblast crosstalk drives Arg1-dependent lung fibrosis via ornithine loading.
bioRxiv : the preprint server for biology
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling.
Nature communications
Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis.
NPJ precision oncology
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.
Nature communications
PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors.
Nature Cancer
Phase-Separated Biomolecular Condensation in Cancer: New Horizons and Next Frontiers.
Cancer discovery
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.
Nature genetics
The essential chaperone DNAJC17 activates HSP70 to coordinate RNA splicing and G2-M progression.
bioRxiv : the preprint server for biology
Author Correction: 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib.
Communications biology
FET fusion oncoproteins disrupt physiologic DNA repair networks and induce ATR synthetic lethality in cancer.
Research square
3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib.
Communications biology
GATOR2-dependent mTORC1 activity is a therapeutic vulnerability in FOXO1 fusion-positive rhabdomyosarcoma.
JCI insight
Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC.
JTO clinical and research reports
AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer.
Cancer discovery
Primary and metastatic tumors exhibit systems-level differences in dependence on mitochondrial respiratory function.
PLoS biology
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer.
The Journal of clinical investigation
Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells.
Science translational medicine
Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer.
The Journal of clinical investigation
Digital multiplexed analysis of circular RNAs in FFPE and fresh non-small cell lung cancer specimens.
Molecular oncology
Evolution of metastasis: new tools and insights.
Trends in cancer
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids.
Journal of visualized experiments : JoVE
DDX56 modulates post-transcriptional Wnt signaling through miRNAs and is associated with early recurrence in squamous cell lung carcinoma.
Molecular cancer
Targeting AXL in NSCLC.
Lung Cancer (Auckland, N.Z.)
Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote virus detection and cancer.
Cell reports
Inhibition of SHP2 as an approach to block RAS-driven cancers.
Advances in cancer research
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Stepwise evolution of therapy resistance in AML.
Cancer cell
Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts.
Science (New York, N.Y.)
Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.
Current opinion in chemical biology
Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis.
Oncogenesis
Long non-coding RNA ESCCAL-1 promotes esophageal squamous cell carcinoma by down regulating the negative regulator of APOBEC3G.
Cancer letters
Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma.
Nature communications
Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
EGFR targeted therapy resistance: current status, challenges, and future outlook.
Journal of thoracic disease
Betacellulin drives therapy-resistance in glioblastoma.
Neuro-oncology
AXL targeting abrogates autophagic flux and induces immunogenic cell death in drug resistant cancer cells.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Overcoming the challenges of cancer drug resistance through bacterial-mediated therapy.
Chronic diseases and translational medicine
Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers.
Cell reports
CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs.
The Journal of clinical investigation
Engineering Multidimensional Evolutionary Forces to Combat Cancer.
Cancer discovery
Dampening oncogenic RAS signaling.
Science (New York, N.Y.)
Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.
Current oncology reports
Polytherapy and Targeted Cancer Drug Resistance.
Trends in cancer
Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.
The Journal of experimental medicine
Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology.
Trends in molecular medicine
Immunohistochemistry to Study YAP in Human Tissue Samples.
Methods in molecular biology (Clifton, N.J.)
Differential subcellular localization regulates oncogenic signaling by ROS1 kinase fusion proteins.
Cancer research
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.
Nature medicine
Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.
Clinical lung cancer
Circulating tumor DNA analysis in patients with EGFR mutant lung cancer.
Journal of thoracic disease
Compensation of select proteostasis networks after Hsp70 inhibition in cancer.
Journal of cell science
Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway.
Science (New York, N.Y.)
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
Nature cell biology
IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer.
The Journal of clinical investigation
Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.
Annals of translational medicine
BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations.
JCO precision oncology
The evolving understanding of immunoediting and the clinical impact of immune escape.
Journal of thoracic disease
Imaging PD-L1 Expression with ImmunoPET.
Bioconjugate chemistry
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.
Nature genetics
Understanding and targeting resistance mechanisms in NSCLC.
Nature reviews. Cancer
Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer.
Nature communications
Current Landscape of Targeted Therapy in Lung Cancer.
Clinical pharmacology and therapeutics
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.
Nature communications
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
Journal of the National Cancer Institute
A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases.
The oncologist
Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma.
NPJ precision oncology
Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution.
Scientific reports
Dividing and conquering the variation among variants in EML4-ALK lung cancer.
Translational cancer research
CD74-ROS1 Fusion in NSCLC Detected by Hybrid Capture-Based Tissue Genomic Profiling and ctDNA Assays.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer.
Cancer research
Metastasis: From head to tail.
Cell cycle (Georgetown, Tex.)
Inactivation of Capicua drives cancer metastasis.
Nature genetics
Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Proceedings of the National Academy of Sciences of the United States of America
HSP70 dependence in rhabdomyosarcoma: Seed or soil?
Cell cycle (Georgetown, Tex.)
Combined chemical-genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcoma.
Proceedings of the National Academy of Sciences of the United States of America
Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance.
Clinical lung cancer
A framework for understanding and targeting residual disease in oncogene-driven solid cancers.
Nature medicine
RAS signaling in ALK fusion lung cancer.
Small GTPases
Tracking Down Response and Resistance to TRK Inhibitors.
Cancer discovery
RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancer.
Molecular & cellular oncology
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.
Nature medicine
AXL receptor tyrosine kinase as a therapeutic target in NSCLC.
Lung Cancer (Auckland, N.Z.)
The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors.
Molecular & cellular oncology
AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.
PloS one
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
Nature genetics
RAS-MAPK in ALK targeted therapy resistance.
Cell cycle (Georgetown, Tex.)
YAP in MAPK pathway targeted therapy resistance.
Cell cycle (Georgetown, Tex.)
Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer.
Journal of translational medicine
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.
Cancer treatment reviews
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.
Proceedings of the National Academy of Sciences of the United States of America
The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.
Clinical cancer research : an official journal of the American Association for Cancer Research
Recent advances in personalized lung cancer medicine.
Personalized medicine
Genetics and biomarkers in personalisation of lung cancer treatment.
Lancet (London, England)
FGFR fusions in the driver's seat.
Cancer discovery
Mechanisms of resistance to EGFR targeted therapies.
Cancer biology & therapy
Secrets of drug resistance in NSCLC exposed by new molecular definition of EMT.
Clinical cancer research : an official journal of the American Association for Cancer Research
Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.
Cancer discovery
Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients.
Chemotherapy research and practice
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Nature genetics
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.
Proceedings of the National Academy of Sciences of the United States of America
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
Clinical cancer research : an official journal of the American Association for Cancer Research
Analysis of K-Ras phosphorylation, translocation, and induction of apoptosis.
Methods in enzymology
PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis.
Molecular cell
Analysis of Ras activation in living cells with GFP-RBD.
Methods in enzymology
Analysis of Ras and Rap activation in living cells using fluorescent Ras binding domains.
Methods (San Diego, Calif.)
Cannabinoid receptor-induced neurite outgrowth is mediated by Rap1 activation through G(alpha)o/i-triggered proteasomal degradation of Rap1GAPII.
The Journal of biological chemistry
Identification of a Ras GTPase-activating protein regulated by receptor-mediated Ca2+ oscillations.
The EMBO journal
Membranes as messengers in T cell adhesion signaling.
Nature immunology
Ras activation in Jurkat T cells following low-grade stimulation of the T-cell receptor is specific to N-Ras and occurs only on the Golgi apparatus.
Molecular and cellular biology
Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment.
Molecular cell
Rap1 up-regulation and activation on plasma membrane regulates T cell adhesion.
The Journal of cell biology
Intersectin activates Ras but stimulates transcription through an independent pathway involving JNK.
The Journal of biological chemistry
Ras pathway signaling on endomembranes.
Current opinion in cell biology
Ras signalling on the endoplasmic reticulum and the Golgi.
Nature cell biology
Toxoplasma gondii Rab5 enhances cholesterol acquisition from host cells.
Cellular microbiology